Abstract
Background: Mild cognitive impairment (MCI) is a syndrome heterogeneous with regards to etiology and prognosis. Amyloid imaging enables to visualize a hallmark pathology of Alzheimer’s disease (AD). Therefore we aimed to assess the usefulness of [11C]PiB PET for predicting clinical outcome of MCI patients after an interval of 2 years.
Methods: In 28 MCI participants with a global CDR rating at baseline of 0.5 a baseline examination including clinical assessments and [11C]PiB PET imaging and a clinical follow-up examination after a planned interval of 24 months were performed. Predictive values and accuracy of amyloid-positive and negative scans for conversion to dementia of any type and to dementia due to AD were calculated and compared to neuropsychological tests and ApoE genotyping.
Results: Of 17 MCI patients who were amyloid-positive at baseline converted 9 to dementia all of the AD type. 3 of the 11 amyloid-negative MCI subjects converted to dementia but none to dementia due to AD. PPV, NPV and accuracy (to dementia: 0.53, 0.73 and 0.61; to AD: 0.53, 1.00 and 0.70) was comparable to neuropsychological tests and superior to ApoE genotyping.
Conclusion: All MCI subjects who converted to dementia due to AD were amyloid-positive. However, only 50% of these MCI due to AD, intermediate likelihood, patients developed manifest dementia due to AD after 24 months limiting the usefulness of [11C]PiB PET for individual prediction of clinical outcome.
Keywords: Mild cognitive impairment, positron emission tomography, pittsburgh compound b, prospective study, conversion.
Current Alzheimer Research
Title:The Usefulness of Amyloid Imaging in Predicting the Clinical Outcome After Two Years in Subjects with Mild Cognitive Impairment
Volume: 10 Issue: 1
Author(s): Timo Grimmer, Carolin Wutz, Alexander Drzezga, Stefan Förster, Hans Förstl, Marion Ortner, Robert Perneczky and Alexander Kurz
Affiliation:
Keywords: Mild cognitive impairment, positron emission tomography, pittsburgh compound b, prospective study, conversion.
Abstract: Background: Mild cognitive impairment (MCI) is a syndrome heterogeneous with regards to etiology and prognosis. Amyloid imaging enables to visualize a hallmark pathology of Alzheimer’s disease (AD). Therefore we aimed to assess the usefulness of [11C]PiB PET for predicting clinical outcome of MCI patients after an interval of 2 years.
Methods: In 28 MCI participants with a global CDR rating at baseline of 0.5 a baseline examination including clinical assessments and [11C]PiB PET imaging and a clinical follow-up examination after a planned interval of 24 months were performed. Predictive values and accuracy of amyloid-positive and negative scans for conversion to dementia of any type and to dementia due to AD were calculated and compared to neuropsychological tests and ApoE genotyping.
Results: Of 17 MCI patients who were amyloid-positive at baseline converted 9 to dementia all of the AD type. 3 of the 11 amyloid-negative MCI subjects converted to dementia but none to dementia due to AD. PPV, NPV and accuracy (to dementia: 0.53, 0.73 and 0.61; to AD: 0.53, 1.00 and 0.70) was comparable to neuropsychological tests and superior to ApoE genotyping.
Conclusion: All MCI subjects who converted to dementia due to AD were amyloid-positive. However, only 50% of these MCI due to AD, intermediate likelihood, patients developed manifest dementia due to AD after 24 months limiting the usefulness of [11C]PiB PET for individual prediction of clinical outcome.
Export Options
About this article
Cite this article as:
Grimmer Timo, Wutz Carolin, Drzezga Alexander, Förster Stefan, Förstl Hans, Ortner Marion, Perneczky Robert and Kurz Alexander, The Usefulness of Amyloid Imaging in Predicting the Clinical Outcome After Two Years in Subjects with Mild Cognitive Impairment, Current Alzheimer Research 2013; 10 (1) . https://dx.doi.org/10.2174/1567205011310010011
DOI https://dx.doi.org/10.2174/1567205011310010011 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Natural Steroids and Androgen Antagonists used as Neuroprotection in Common Neurological Disorders
CNS & Neurological Disorders - Drug Targets Biomarkers of Alzheimer's Disease Risk in Peripheral Tissues; Focus on Buccal Cells
Current Alzheimer Research AtreMorine Treatment Regulates DNA Methylation in Neurodegenerative Disorders: Epigenetic and Pharmacogenetic Studies
Current Pharmacogenomics and Personalized Medicine Evaluation of Acetylcholinesterase and Prolyl Oligopeptidase Inhibition of Novel Amino acid-functionalized Stigmasterol and Ursolic Acid Derivatives
Current Organic Chemistry Monoamine Receptors and Signal Transduction Mechanisms in Suicide
Current Psychiatry Reviews Molecular Interaction of Human Brain Acetylcholinesterase with a Natural Inhibitor Huperzine-B: An Enzoinformatics Approach
CNS & Neurological Disorders - Drug Targets Alzheimer´s Disease-associated Aβ42 Peptide: Expression and Purification for NMR Structural Studies
Current Chemical Biology Hyperhomocysteinemia, Pteridines and Oxidative Stress
Current Drug Metabolism The Metabolic Rationale for a Lack of Cross-reactivity Between Sulfonamide Antimicrobials and Other Sulfonamide-containing Drugs
Drug Metabolism Letters Editorial (Thematic Issue: Ceramics, Nanotubes, Advanced Materials: Theoretical and Experimental Structure-Property Relationships Part IV)
Current Physical Chemistry Clinical Potential of Yi-Gan San (Yokukansan) for the Treatment of Psychiatric Disorders
Current Psychiatry Reviews EDITORIAL: “The Faces of Mania: The Legacy of Athanasios Koukopoulos”
Current Neuropharmacology Associations of Cerebrovascular and Alzheimer’s Disease Pathology with Brain Atrophy
Current Alzheimer Research New Insights into the Chemistry and Antioxidant Activity of Coumarins
Current Topics in Medicinal Chemistry In Vivo Application of beta Amyloid Oligomers: A Simple Tool to Evaluate Mechanisms of Action and New Therapeutic Approaches
Current Pharmaceutical Design Cerebrovascular Complications After Heart Transplantation
Current Cardiology Reviews Adenosine and Stroke: Maximizing the Therapeutic Potential of Adenosine as a Prophylactic and Acute Neuroprotectant
Current Neuropharmacology Ring Finger Ubiquitin Protein Ligases and Their Implication to the Pathogenesis of Human Diseases
Current Pharmaceutical Design Arundic Acid (ONO-2506) Ameliorates Delayed Ischemic Brain Damage by Preventing Astrocytic Overproduction of S100B
Current Drug Targets - CNS & Neurological Disorders Unmasking Sex-Based Disparity in Neuronal Metabolism
Current Pharmaceutical Design